Coherus Oncology’s Q4 Loss of $0.34 Wide of Estimates, Revenues Fall 76%
Coherus Oncology posted a Q4 adjusted loss of $0.34 per share, 9.7% below consensus and wider than last year’s $0.28 deficit, on revenues of $12.75 million missing estimates by 2.9% and down from $54.14 million a year earlier. Shares have risen 28.2% year-to-date despite four straight quarters of EPS shortfalls.
1. Q4 Financial Results
Coherus Oncology reported an adjusted loss of $0.34 per share for the quarter ended December 2025, missing the consensus estimate of a $0.31 loss and widening from a $0.28 deficit a year earlier. Revenue of $12.75 million fell 2.9% short of the $13.1 million forecast and declined 76% from $54.14 million in the prior-year period.
2. Year-to-Date Share Performance
Shares have climbed 28.2% since January 1 while the S&P 500 fell 1.5%, reflecting investor optimism despite four consecutive quarters of EPS misses.
3. Outlook and Consensus Estimates
Analysts project a Q1 adjusted loss of $0.27 per share on $14.68 million in revenue and a fiscal 2026 loss of $0.50 on $96.24 million, with mixed estimate revisions supporting a hold rating within the medical-biomedical industry.